Literature DB >> 10454874

The use of olanzapine for movement disorder in Huntington's disease: a first case report.

H C Dipple.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10454874      PMCID： PMC1736408          DOI： 10.1136/jnnp.67.1.123

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  10 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

3.  Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

Authors:  Georg Karpel-Massler; Richard Eric Kast; Mike-Andrew Westhoff; Annika Dwucet; Nathalie Welscher; Lisa Nonnenmacher; Michal Hlavac; Markus David Siegelin; Christian Rainer Wirtz; Klaus-Michael Debatin; Marc-Eric Halatsch
Journal:  J Neurooncol       Date:  2014-12-19       Impact factor: 4.130

Review 4.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 5.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 6.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

8.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

Review 9.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 10.  Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.

Authors:  Adaze Bijou Enogieru; William Haylett; Donavon Charles Hiss; Soraya Bardien; Okobi Eko Ekpo
Journal:  Oxid Med Cell Longev       Date:  2018-06-27       Impact factor: 6.543
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.